Age-related change in the retinoid X receptor beta gene expression in peripheral blood mononuclear cells of healthy volunteers: effect of 13-cis retinoic acid supplementation.
The regulation of cell growth and differentiation and also expression of a number of genes by retinoids are mediated by nuclear retinoid receptors (RARs and/or RXRs). In this study we investigated age-related alteration in both RAR and RXR receptor subtypes gene expression and tissue transglutaminase (tTG) activity before and after supplementation with 13-cis retinoic acid (13cRA) in human peripheral blood mononuclear cells (PBMCs). Healthy men (40) were divided in two groups according to their age (young group: 26.1+/-4.1 years and old group: 65.4+/-3.8 years). Each volunteer received 13cRA (Curacné), 0.5mg/(kgday)) during a period of 4 weeks. We have shown that RXRbeta expression was decreased significantly (p=0.0108) in PBMCs of elderly men when compared to that of young volunteers. Distribution of retinoic acid receptor subtype expression in PBMCs was found in the order: RXRbeta>RARgamma>RXRalpha>RARalpha. The tTG activity in PBMCs reflected a trend to be enhanced after 13-cis retinoic acid supplementation. In conclusion, we demonstrate a significant decrease in the expression of RXRbeta subtype of rexinoid receptors in PBMCs of healthy elderly men. Our data suggest that in healthy elderly men reduction of RXRbeta expression in PBMCs might be a common feature of physiological senescence.
Brtko
J
J
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Laboratory of Molecular Endocrinology, Vlarska 3, 833 06 Bratislava, Slovak Republic. julius.brtko@savba.sk
Rock
E
E
Nezbedova
P
P
Krizanova
O
O
Dvorcakova
M
M
Minet-Quinard
R
R
Farges
M-C
MC
Ribalta
J
J
Winklhofer-Roob
B M
BM
Vasson
M-P
MP
Macejova
D
D
D000328:Adult; D000367:Age Factors; D000368:Aged; D000375:Aging / Q000097:blood / Q000235:genetics*; D000077556:Alitretinoin; D016922:Cellular Senescence / Q000187:drug effects / Q000235:genetics; D019587:Dietary Supplements; D015536:Down-Regulation / Q000187:drug effects; D019204:GTP-Binding Proteins; D006801:Humans; D015474:Isotretinoin / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012333:RNA, Messenger / Q000097:blood; D018168:Receptors, Retinoic Acid / Q000235:genetics; D012016:Reference Values; D000072482:Retinoic Acid Receptor alpha; D047490:Retinoid X Receptor alpha / Q000235:genetics; D049230:Retinoid X Receptor beta / Q000097:blood / Q000235:genetics*; D013997:Time Factors; D011503:Transglutaminases / Q000097:blood; D014212:Tretinoin / Q000097:blood; D000097768:Retinoic Acid Receptor gamma
D000077556:Alitretinoin; D019204:GTP-Binding Proteins; D015474:Isotretinoin; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012333:RNA, Messenger; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D047490:Retinoid X Receptor alpha; D049230:Retinoid X Receptor beta; D011503:Transglutaminases; D014212:Tretinoin; D000097768:Retinoic Acid Receptor gamma; C000607071:RARA protein, human